Physician profile
Anthony M Scott
NPI 1689639494
$2,147.07
in general payments reported to CMS, 2019-2025
25 companies · $232 in 2025
The $232 reported for 2025 was more than what 78% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $171 · 2021: $236 · 2022: $153 · 2023: $416 · 2024: $213 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $332.94 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $329.83 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $301.44 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $143.10 | 2019-2022 | |
| Pfizer INC. | $135.40 | 2019-2024 | |
| Sanofi Pasteur INC. | $125.99 | 2019-2024 | |
| Cranial Technologies, INC | $103.11 | 2019-2024 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $81.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $75.05 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Arbor Pharmaceuticals, INC. | $73.53 | 2019 | |
| Corium, LLC | $52.84 | 2022-2025 | Azstarys |
| American Regent | $52.35 | 2025 | Injectafer |
| Alk-Abello, INC | $48.55 | 2021-2025 | Neffy, Odactra, Grastek |
| Seqirus USA INC | $41.39 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Genentech USA, INC. | $37.58 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immedica Pharma US, INC. | $34.82 | 2023 | |
| Intrabio INC | $27.90 | 2025 | Aqneursa |
| Phadia US INC. | $25.96 | 2025 | Immunocap |
| Tela Bio, INC. | $25.13 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Abbott Laboratories | $20.75 | 2025 | Id Now Instrument |
| Verrica Pharmaceuticals INC. | $19.63 | 2024 | Ycanth |
| Zevra Therapeutics INC | $18.26 | 2025 | Olpruva |
| Galderma Laboratories, L.P. | $14.71 | 2019 | |
| Aytu Biopharma, INC. | $14.08 | 2024 | Karbinal |
| Glaxosmithkline, LLC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.